The Strengthening Collaboration for Operating Pharmacovigilance in Europe Joint Action organised a Flagship Event on 23 November 2016 in London. The event brought together representatives from 22 national regulatory agencies, EC, EMA, UMC, ISoP, and academia.
Over the past three years the SCOPE Joint Action gathered information, and reviewed the pharmacovigilance practices in the network. The Flagship Event was organised to showcase SCOPE’s findings together with the tools and outputs from this unique Joint Action. The Flagship Event was a success with great contribution from all participants throughout the day. Delegates from across the Europe participated in four sessions:
Session 1 – Effective Systems for Managing ADRs and Signals
The first session was dedicated to the SCOPE's findings and developments in the area of collection and analysis of suspected adverse drug reaction (ADR) reports and the management of safety signals for medicines.
Session 2 - Evaluating and Maximising Risk Benefit Assessment
The next part of the meeting focused on the SCOPE achievements in the areas of risk communication, risk benefit assessment, and quality management systems.
Session 3 - An Overview of SCOPE achievements
The third session built on the insights presented during the morning sessions and focused on maximising the potential of SCOPE's results, benefits for patients, value of the project in the pharmacovigilance network, and sustainability aspect.
Session 4 – Questions and panel discussion
The panel discussion focused on maximising outputs of SCOPE Joint Action in the pharmacovigilance network and discussion about the potential further activities in the network.
Recordings and videos from the meeting will published on the website soon.